SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…
Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance…
To acquire R&D center at Saint-Julien-en-Genevois, France To add Drug Discovery & Preclinical Development capabilities in Biologics & Antibody Drug…
Benchling AI debuts alongside major new capabilities for antibody discovery, automated data analysis, and development BOSTON, Oct. 14, 2025 /PRNewswire/…
Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1 trial of ‘2510 is expected to be initiated before…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…